Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2019-05-13 Environmental & Social …
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Environmental & Social Information Classification · 99% confidence The document is a press release dated May 13, 2019, announcing that NEPHROCHECK biomarkers were included in the ERAS 'Guidelines for Perioperative Care in Cardiac Surgery'. It details the significance of this inclusion, provides context about AKI, and includes boilerplate information about the company (bioMérieux) and contacts. This format—a news announcement about a clinical/regulatory development or product update, rather than a formal periodic financial report (like 10-K or IR) or a transcript—is characteristic of a general press release. Since there is no specific category for 'Press Release' or 'Product/Clinical Update', and it is not a formal regulatory filing like a 10-K, AR, or ER, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for non-standard filings.
2019-05-13 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated May 13, 2019, announcing that NEPHROCHECK biomarkers were included in the ERAS 'Guidelines for Perioperative Care in Cardiac Surgery'. It details the significance of this inclusion, provides context about AKI, and includes boilerplate information about the company (bioMérieux) and contacts. This format—a news announcement about a clinical/regulatory development or product update, rather than a formal periodic financial report (like 10-K or IR) or a transcript—is characteristic of a general press release. Since there is no specific category for 'Press Release' or 'Product/Clinical Update', and it is not a formal regulatory filing like a 10-K, AR, or ER, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for non-standard filings. FY 2019
2019-05-13 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, which is a regulatory requirement in France (AMF). This type of filing, detailing the total share count and voting rights, is a specific type of regulatory disclosure. While it is a periodic report, it is not a comprehensive financial report (10-K or IR). It most closely aligns with a specific regulatory disclosure concerning share capital structure and voting rights. Given the options, this specific disclosure about voting rights and share count is not explicitly covered by a unique code like DVA (which is for voting *results*), nor is it a general earnings release or management discussion. It is a mandatory regulatory filing concerning share structure. Since there isn't a specific code for 'Voting Rights/Share Count Disclosure', the most appropriate general regulatory category is RNS (Regulatory Filings), as it is a mandatory filing that doesn't fit the other specific financial or corporate action categories. However, upon re-evaluating the definitions, this document is a direct report of share/voting data, not an announcement *about* a report. If we look closely at the content, it is a direct disclosure of the share count and voting rights as of a specific date (30/04/2019). This is a very specific type of regulatory filing. Since RNS is the fallback, and no other code fits this specific monthly share/vote count disclosure, RNS is the best fit among the provided options for a mandatory, non-financial, non-management-change regulatory update.
2019-05-06 French
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – First-Quarter 2019 Business Review" and explicitly states it "released its business review for the three months ended March 31, 2019." It contains detailed financial figures, sales analysis by region and application, and operating highlights for the first quarter. This structure and content align perfectly with a comprehensive financial report covering a period shorter than a year, which corresponds to the Interim / Quarterly Report definition. It is not merely an announcement (RPA) as it contains the full data, nor is it the Annual Report (10-K). Q1 2019
2019-04-24 English
Information financière trimestrielle / Information financière du premier trimestre
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial update for bioMérieux for the first quarter of 2019. It provides detailed revenue figures, growth analysis by region and application, and information on recent acquisitions and partnerships. It is a comprehensive report of financial performance for a period shorter than a full fiscal year, containing substantive financial data and analysis, which fits the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-04-24 French
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 99% confidence The document is extremely short (745 characters) and its title explicitly states: "Communiqué de mise à disposition du document de référence incluant le rapport financier annuel au 31 décembre 2018" (Announcement of the availability of the reference document including the annual financial report as of December 31, 2018). The text confirms that the annual report is 'mis à la disposition du public' (made available to the public) and directs the reader to the website to consult it. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report is available elsewhere should be classified as a Report Publication Announcement (RPA), not the full report itself (10-K).
2019-04-15 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.